Liver cirrhosis developed after ketoconazole-induced acute hepatic injury

Journal of Gastroenterology and Hepatology (Australia)

Volumn 18, Issue 12, 2003, Pages 1426-1429

  Kim, Tae Hyung ^a   Kim, Byung Ho ^a,c   Kim, Youn Wha ^a   Yang, Dal Mo ^b   Han, Yo Seb ^a   Dong, Seok Ho ^a   Kim, Hyo Jong ^a   Chang, Young Woon ^a   Lee, Joung Il ^a   Chang, Rin ^a  

^a Kyung Hee University Hospital   (South Korea)

^b Gachon University College of Medicine   (South Korea)

^c Kyung Hee University College of Medicine   (South Korea)

Author keywords

Ketoconazole; Liver cirrhosis

Indexed keywords

KETOCONAZOLE;

ABDOMEN; ACUTE DISEASE; ADULT; ANOREXIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DISEASE COURSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; JAUNDICE; LABORATORY TEST; LAPAROSCOPY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER INJURY; LIVER WEIGHT; MEDICAL EXAMINATION; NAUSEA; ONYCHOMYCOSIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SIDE EFFECT;

EID: 9144232449     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2003.02852.x     Document Type: Article

References (14)

1. Medoff G, Kobayashi GS. Strategies in the treatment of systemic fungal infections. N. Engl. J. Med. 1980; 302: 145-55.
2. Dismukes WE, Stamm AM, Graybill JR et al. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. Ann. Intern. Med. 1983; 98: 13-20.
3. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy: analysis of 33 cases. Gastroenterology 1984; 86: 503-13.
4. Janssen PAJ, Symoens JE. Hepatic reactions during ketoconazole treatment. Am. J. Med. 1983; 74: 80-5.
5. Chien RN, Yang LJ, Lin PY, Liaw YF. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology 1997; 25: 103-7.
6. Stricker BHC, Block APR, Bronkhorst FB, Van Parys GE, Desmet VJ. Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases. J. Hepatol. 1986; 3: 399-406.
7. Duarte PA, Chow CC, Simmons F, Ruskin J. Fatal hepatitis associated with ketoconazole therapy. Arch. Intern. Med. 1984; 144: 1069-70.
8. Kim HJ, Kim BH, Han YS et al. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single center retrospective study. Am. J. Gastroenterol. 2001; 96: 165-9.
9. Jung SH, Kim BH, Dong SH et al. Clinical features of Korean patients with autoimmune hepatitis diagnosed since 1991. Korean J. Gastroenterol. 2001; 37: 362-9.
10. Kingham JGC. Dissecting out cryptogenic liver disease. Gut 2000; 47: 328-9.
11. Ku NO, Gish R, Wright TL, Omary MB. Keratin 8 mutations in patients with cryptogenic liver disease. N. Engl. J. Med. 2001; 344: 1580-7.
12. Zatloukal K, Stumptner C, Lehner M et al. Cytokeratin 8 protects from hepatotoxicity, and its ratio to cytokeratin 18 determines the ability of hepatocytes to form Mallory bodies. Am. J. Pathol. 2000; 156: 1263-74.
13. Cho JW, Ko YH, Kim YK et al. Hepatic septal fibrosis induced by long-term use of ketoconazole. Korean J. Hepatol. 2000; 6: 241-5.
14. Zakim D, Boyer TD. Hepatology: a Textbook of Liver Disease. Philadelphia: W. B. Saunders, 1996.